Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes.
An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.
The SKNJCT-003 study, conducted at nine clinical sites in the United States, is expected to enroll 60 patients.
The investigational treatment, D-MNA, was well tolerated across both dosage levels—100μg and 200μg—without dose-limiting toxicities or serious adverse events, Medicus said. No systemic effects or significant abnormalities in laboratory parameters, vital signs, ECGs, or physical examinations were observed.
“These encouraging interim results bring us one step closer to delivering a novel, non-invasive treatment for BCC,” said CEO Dr Raza Bokhari.
Medicus plans to submit the interim analysis to the US Food and Drug Administration as part of a request for a Type C meeting in the second quarter of 2025, seeking regulatory alignment and potential acceleration of the clinical program.
The company is also expanding its research internationally, with a planned clinical trial in the United Arab Emirates involving 36 patients across four medical centers, including Cleveland Clinic Abu Dhabi and American Hospital Dubai.
Basal cell carcinoma is the most common type of skin cancer, typically treated with surgery. Medicus’ investigational therapy aims to offer a non-invasive alternative.
Shares of Medicus gained almost 8% in early trading Thursday before settling around 2.4% above opening levels.